Publications

Pasipanodya JG, Gumbo T. Clinical and toxicodynamic evidence that high dose pyrazinamide is not more hepatotoxic than current low doses. Antimicrob Agents Chemother. 2010 May 3.

Deshpande D, Srivastava S, Meek C, Leff R, Hall GS, Gumbo T. Moxifloxacin Pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother. 2010 Jun;54(6):2534-9.

Shaw JET, Pasipanodya JG, Gumbo T. Meningeal tuberculosis has very poor long term mortality despite standard therapy. Medicine (Baltimore) 2010; 89 (3): 189-95.

Deshpande D, Srivastava S, Meek C, Leff R, Gumbo T. Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification By Use of A Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium. Antimicrob Agents Chemother. 2010 May;54(5):1728-33.

Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis. 2010 Apr 15;201(8):1225-31.

Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother. 2010 Apr;54(4):1484-91.

Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009 Dec;29(12):1468-81. Review.

Gumbo T, Dona CS, Meek C, Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother. 2009 Aug;53(8):3197-204. Epub 2009 May 18.

Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis. 2008;60(3):329-31.

Sabol K, Gumbo T. Anidulafungin in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2008;4(1):71-8.

Gumbo T. Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy. Curr Opin Drug Discov Devel. 2008;11(1):32-42

Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51(11):3781-8.

Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.Antimicrob Agents Chemother. 2007;51(7):2329-36.

Gumbo T. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies. Curr Opin Infect Dis. 2007;20(6):587-91.

Gumbo T, Drusano GL, Liu W, Kulawy RW, Fregeau C, Hsu V, Louie A. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother. 2007;51(3):968-74.

Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, Drusano GL. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis. 2007;195(2):194-201.